Comparative analysis of ide-cel and cilta-cel in patients with Relapsed/Refractory multiple myeloma: A nationwide, retrospective, real-world analysis across Austria
Irene Straßl(Krankenhaus der Elisabethinen), Krauth Maria-Theresa(Medical University of Vienna), Nina Worel(Medical University of Vienna), Theresa Lentner(Karl Landsteiner University of Health Sciences), Eduard Schulz(Medical University of Graz), Sigrid Machherndl‐Spandl(Krankenhaus der Elisabethinen), Michael Leisch(Paracelsus Medical University), Dominik Wolf(Innsbruck Medical University), Holger Rumpold(Innsbruck Medical University), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Normann Steiner(Innsbruck Medical University), Wolfgang Willenbacher(Innsbruck Medical University), Annkristin Heine(Medical University of Graz), Thomas Melchardt(Paracelsus Medical University), Johannes Clausen(Johannes Kepler University of Linz), Dagmar Wipplinger(Krankenhaus der Elisabethinen), Peter Neumeister(Medical University of Graz), Petra Pichler(Universitätsklinikum St. Pölten), Alexander Nikoloudis(Johannes Kepler University of Linz), Lina Zoe Ruesing(Medical University of Vienna), Hermine Agis(Medical University of Vienna)
Cited by 0
Related Papers
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
|Blood|2011|448
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
|The Lancet Haematology|2020|351
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
|Blood Cancer Journal|2015|273